Alcon AG vs Anheuser-Busch Inbev SA — how do they compare? Alcon AG trades at $72.48 (market cap $36.44B), while Anheuser-Busch Inbev SA trades at $79.59 (market cap $159.01B). The key difference: Anheuser-Busch Inbev SA is far larger — about 4.4× Alcon AG's market cap, and Anheuser-Busch Inbev SA pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| ALC | BUD | |
|---|---|---|
Market Cap | $36.44B | $159.01B |
Sector | Health | Consumer Staples |
52-Week High | $90.12 | $86.48 |
52-Week Low | $62.02 | $57.93 |
Enterprise Value | $40.28B | $223.42B |
Dividend Yield | 0.48% | 1.67% |
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →